Good & Great Science Outside the Academy
I propose to speak about my experience directing both a virtual research effort that resulted in my discovering the cause of my daughter's genetic illness and unrelated effort to prosecute the pre-clinical and clinical development of a drug using a similar virtual model. Both efforts were international in scope and required the coordination of dozens of scientists and clinicians to contribute in a just-in-time fashion their expertise. Both efforts resulted in significant scientific publications and clinical testing as well as market validation of the drug product.
Though these scientific projects are not scalable, they are capable of addressing very focused and in some cases high value questions in the form of clinical hypotheses.
Dr. Rienhoff is a San Francisco Bay area clinical scientist and entrepreneur. He was a partner at the venture firm New Enterprise Associates. He was a founding director of such companies as Healtheon/WebMD (HLTH) and Aurora Biosciences (ABSC). In 1998, he founded DNA Sciences, a company focused on genetic discoveries. He is also Director of MyDaughtersDNA.org, an advocacy organization dedicated to understanding the genetics of rare diseases.
Dr. Rienhoff founded FerroKin BioSciences in 2007 and was Chief Executive Officer until its acquisition by Shire Pharmaceuticals in 2012.
Dr. Rienhoff is an Adjunct Scientist at the Children’s Hospital Oakland Research Institute. He trained in mathematics, medicine, and genetics at Harvard University, Johns Hopkins University, and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received a Doctor of Medicine degree from Johns Hopkins University School of Medicine and a Bachelor of Arts degree from Williams College.